01265nam0 2200301 i 450 SUN007235520091103120000.088-87222-00-220091103d1997 |0itac50 baitaIT|||| |||||Rilievi di antiche fabbriche padovanepresentazione di Giulio Bresciani Alvareztesti di Pierluigi FantelliPadova : La garangola[1997]103 p. : ill. ; 33x35 cmContiene la ripr. facs. di tavole dei rilievi eseguiti dal 1889 al 1923.MonumentiPadovaRilieviFISUNC026797PadovaSUNL000007720.94532121Fantelli, Pier LuigiSUNV057596Bresciani Alvarez, GiulioSUNV057597La garangolaSUNV005667650ITSOL20181109RICASUN0072355BIBLIOTECA DEL DIPARTIMENTO DI ARCHITETTURA E DISEGNO INDUSTRIALE01 PREST FF 01 50325 BIBLIOTECA DEL DIPARTIMENTO DI ARCHITETTURA E DISEGNO INDUSTRIALEIT-CE010750325PREST FFpaRilievi di antiche fabbriche padovane1415030UNICAMPANIA02937nam 22006612 450 991046539200332120160524144107.01-107-23816-11-107-30188-21-139-51929-81-107-30917-41-107-31472-01-107-30593-41-107-30697-31-299-25737-2(CKB)2560000000098608(EBL)1113111(OCoLC)828302501(SSID)ssj0000833246(PQKBManifestationID)11512045(PQKBTitleCode)TC0000833246(PQKBWorkID)10935740(PQKB)11790994(UkCbUP)CR9781139519298(MiAaPQ)EBC1113111(Au-PeEL)EBL1113111(CaPaEBR)ebr10661191(CaONFJC)MIL456987(EXLCZ)99256000000009860820120523d2013|||| uy| 0engur|||||||||||txtrdacontentcrdamediacrrdacarrierFreedom and the construction of EuropeVolume 2Free persons and free states /edited by Quentin Skinner and Martin van Gelderen[electronic resource]Cambridge :Cambridge University Press,2013.1 online resource (xv, 405 pages) digital, PDF file(s)Title from publisher's bibliographic system (viewed on 05 Oct 2015).1-107-03307-1 1-107-31252-3 Includes bibliographical references and indexes.pt. I. Free persons and freedom of action -- pt. II. Free citizens and the state -- pt. III. Freedom and the limits of Europe.Freedom, today perceived simply as a human right, was a continually contested idea in the early modern period. In Freedom and the Construction of Europe an international group of scholars explore the richness, diversity and complexity of thinking about freedom in the shaping of modernity. Volume 2 considers free persons and free states, examining differing views about freedom of thought and action and their relations to conceptions of citizenship. Debates about freedom have been fundamental to the construction of modern Europe, but represent a part of our intellectual heritage that is rarely examined in depth. These volumes provide materials for thinking in fresh ways not merely about the concept of freedom, but how it has come to be understood in our own time.Freedom & the Construction of EuropeLibertyCivil rightsEuropeLiberty.Civil rights323.094Skinner QuentinGelderen Martin vanUkCbUPUkCbUPBOOK9910465392003321Freedom and the construction of Europe2443616UNINA05212nam 2200613 a 450 991014467800332120230607222359.01-282-12300-997866121230090-470-69892-60-470-69838-1(CKB)1000000000687605(EBL)470609(OCoLC)609849592(SSID)ssj0000354362(PQKBManifestationID)11277480(PQKBTitleCode)TC0000354362(PQKBWorkID)10313208(PQKB)10737552(MiAaPQ)EBC470609(Au-PeEL)EBL470609(CaPaEBR)ebr10297729(CaONFJC)MIL212300(EXLCZ)99100000000068760520000329d2002 uy 0engur|n|---|||||txtccrInsulin resistance[electronic resource] a clinical handbook /Andrew J. KrentzOxford ;Malden, Mass. Blackwell Sciencec20021 online resource (202 p.)Description based upon print version of record.0-632-05662-2 Includes bibliographical references and index.Insulin Resistance A Clinical Handbook; Contents; Preface; About the author; Acknowledgements; 1 Pathophysiology of insulin resistance; 1.1 Introduction; 1.2 Normal physiology; 1.2.1 Hormonal regulation of metabolism; 1.2.2 The insulin receptor; 1.2.3 Post-binding events; 1.2.4 Glucose metabolism; 1.2.5 Lipid metabolism; 1.2.6 Protein metabolism; 1.2.7 Ion transport; 1.3 The concept of insulin resistance; 1.3.1 Early studies of insulin action; 1.3.2 Radioimmunoassays for insulin; 1.4 Definitions of insulin resistance; 1.5 Assessment of insulin action in vivo1.5.1 Fasting insulin concentration1.5.2 Dynamic techniques-endogenous insulin; 1.5.3 Dynamic techniques-exogenous insulin; 1.5.4 Mathematical modelling techniques; 1.5.5 Insulin suppression test; 1.5.6 Hyperinsulinaemic euglycaemic clamp technique; 1.5.7 Complementary techniques; 1.6 Mechanisms of insulin resistance; 1.6.1 Genetic defects; 1.6.2 Acquired forms of insulin resistance; 1.6.3 Fetal origins hypothesis; 1.7 Further reading; 2 Insulin resistance in clinical medicine; 2.1 Clinical features; 2.2 Factors influencing insulin sensitivity; 2.2.1 Normal variation in insulin action2.2.2 Sex2.2.3 Age; 2.2.4 Physical exercise; 2.2.5 Tobacco; 2.2.6 Alcohol; 2.3 Physiological states of insulin resistance; 2.3.1 Puberty; 2.3.2 Pregnancy; 2.3.3 Menstrual cycle; 2.3.4 The menopause; 2.4 Severe insulin-resistance syndromes; 2.5 Insulin resistance and cardiovascular risk; 2.5.1 Syndrome X; 2.5.2 Obesity; 2.5.3 Regional adiposity; 2.5.4 Impaired glucose tolerance; 2.5.5 Type 2 diabetes mellitus; 2.5.6 Essential hypertension; 2.5.7 Dyslipidaemia; 2.5.8 Endothelial dysfunction; 2.5.9 Microalbuminuria; 2.5.10 Hyperuricaemia; 2.5.11 Impaired fibrinolysis2.5.12 Polycystic ovary syndrome2.5.13 Non-alcoholic steatohepatitis; 2.6 Other disorders associated with insulin resistance; 2.6.1 Counter-regulatory hormone secretion; 2.6.2 Endocrinopathies; 2.6.3 Chronic renal failure; 2.6.4 Hepatic cirrhosis; 2.6.5 Cardiac failure; 2.7 Miscellaneous inherited disorders; 2.8 Drug-induced insulin resistance; 2.9 Further reading; 3 Management of insulin resistance and associated conditions; 3.1 Non-pharmacological measures; 3.1.1 Medical nutrition therapy; 3.1.2 Physical activity; 3.1.3 Alcohol; 3.1.4 Tobacco; 3.2 Drugs for type 2 diabetes; 3.2.1 Biguanides3.2.2 Thiazolidinediones3.2.3 Sulphonylureas; 3.2.4 Meglitinide analogues; 3.2.5 α-Glucosidase inhibitors; 3.2.6 Insulin; 3.3 Antiobesity drugs; 3.3.1 Sibutramine; 3.3.2 Orlistat; 3.3.3 Leptin; 3.2.4 β3-adrenocepter agonists; 3.4 Lipid-modifying drugs; 3.4.1 Fibric acid derivatives; 3.4.2 Acipimox; 3.4.3 Statins; 3.4.4 Omega-3 fatty acids; 3.5 Antihypertensive drugs; 3.2.4 β-adrenocepter agonists; 3.5.2 Calcium-channel blockers; 3.5.3 Angiotensin converting enzyme inhibitors; 3.5.4 Angiotensin II receptor antagonists; 3.5.5 α1-Receptor blockers; 3.5.6 Selective imidazoline receptor agonists3.5.7 AspirinInsulin resistance, defined as a reduced biological action of insulin, has emerged as a major factor in the development and progression of a number of common non-communicable diseases in man. The role of insulin resistance in the aetiology of type 2 diabetes is particularly well-established. However, insulin resistance has also come to be regarded as a key component of a broader syndrome of common metabolic defects that conspire to increase the risk of atherosclerotic coronary heart disease. The ramifications of insulin resistance now embrace many different medical specialties. The objeInsulin resistanceHandbooks, manuals, etcInsulin resistance616.4/6207Krentz Andrew J937191MiAaPQMiAaPQMiAaPQBOOK9910144678003321Insulin resistance2110860UNINA